Skip to main content

Evidence gap analysis

Strategic analysis of the sufficiency of evidence to obtain reimbursement and HTA approval in Europe and recommendations about evidence generation

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

New version of NABM nomenclature released

On February 15, 2024, the new Nomenclature of Medical Biology Acts (NABM089) was released. Various changes were implemented, including the introduction of new codes and modifications of the existing codes and titles.

The newly introduced codes concern microbiological and biochemical tests and include the following:

  • 1003 “Biological diagnosis of GLUT1 transporter deficiency syndrome” with a tariff of €290.42;
  • 1684 “Faecal calprotectin” with a tariff of €33.8;
  • 5306 “Resistance to macrolides in mycoplasma genitalium” with a tariff of €22.1.

See the details in French here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).